AIM ImmunoTech Inc. cotiza a 0.17 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded rib…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.43 | $-0.69 | $-0.44 | $-1.57 |
| Estimado | $-0.12 | $-0.37 | $-0.94 | $-0.98 |
| Sorpresa | -258.3% | -86.5% | +53.2% | -60.2% |
| Métrica | AIM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -13254.5% | -38.6% | -13215.9% |
| Net Margin | -15861.4% | -33.6% | -15827.8% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -241.4% | -32.0% | -209.4% |
| Current Ratio | 0.53 | 2.84 | -2.31 |
| Debt / Equity | -0.46 | 0.28 | -0.74 |